Health In Tech, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 42/100
What the filing says
Health In Tech reported Q2 2026 revenue of $8.1M (down from $9.3M YoY) and net loss of $2.5M ($0.04 per diluted share). First-half 2026 revenue was $16.8M vs. $17.3M prior year. Contracted Revenue totaled $32.3M; Pipeline Revenue was $66.3M with 15-40% expected conversion. Company raised $6.4M via PIPE financing and reaffirmed full-year 2026 revenue guidance of $45-50M. Distribution partners grew 19.9% YoY to 933.
Why this rating
Declining YoY revenue and negative EBITDA are concerning for a micro-cap. However, PIPE capital raise and large pipeline relative to quarterly revenue provide runway. Event material but not immediately trajectory-ending given forward guidance.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.